25 XP   0   0   10

Ryvu Therapeutics SA
Buy, Hold or Sell?

Let's analyse Ryvu together

PenkeI guess you are interested in Ryvu Therapeutics SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ryvu Therapeutics SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Ryvu Therapeutics SA

I send you an email if I find something interesting about Ryvu Therapeutics SA.

Quick analysis of Ryvu (30 sec.)










What can you expect buying and holding a share of Ryvu? (30 sec.)

How much money do you get?

How much money do you get?
zł0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
zł11.23
Expected worth in 1 year
zł7.60
How sure are you?
17.6%

+ What do you gain per year?

Total Gains per Share
zł-3.62
Return On Investment
-7.1%

For what price can you sell your share?

Current Price per Share
zł50.80
Expected price per share
zł43.50 - zł54.30
How sure are you?
50%

1. Valuation of Ryvu (5 min.)




Live pricePrice per Share (EOD)

zł50.80

Intrinsic Value Per Share

zł-53.41 - zł-63.40

Total Value Per Share

zł-42.18 - zł-52.17

2. Growth of Ryvu (5 min.)




Is Ryvu growing?

Current yearPrevious yearGrowGrow %
How rich?$64m$45.1m$27.6m38.0%

How much money is Ryvu making?

Current yearPrevious yearGrowGrow %
Making money-$5.6m-$5.1m-$514.1k-9.0%
Net Profit Margin-200.3%-24,511.9%--

How much money comes from the company's main activities?

3. Financial Health of Ryvu (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#443 / 1010

Most Revenue
#403 / 1010

Most Profit
#452 / 1010

Most Efficient
#628 / 1010

What can you expect buying and holding a share of Ryvu? (5 min.)

Welcome investor! Ryvu's management wants to use your money to grow the business. In return you get a share of Ryvu.

What can you expect buying and holding a share of Ryvu?

First you should know what it really means to hold a share of Ryvu. And how you can make/lose money.

Speculation

The Price per Share of Ryvu is zł50.80. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ryvu.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ryvu, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is zł11.23. Based on the TTM, the Book Value Change Per Share is zł-0.91 per quarter. Based on the YOY, the Book Value Change Per Share is zł1.88 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is zł0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ryvu.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.30-0.6%-0.28-0.5%-0.28-0.5%0.000.0%0.000.0%
Usd Book Value Change Per Share-0.29-0.6%-0.22-0.4%0.460.9%0.160.3%0.160.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.29-0.6%-0.22-0.4%0.460.9%0.160.3%0.160.3%
Usd Price Per Share14.20-14.96-9.58-13.13-13.13-
Price to Earnings Ratio-11.97--14.22--10.17--22.07--22.07-
Price-to-Total Gains Ratio-49.78--71.75--42.57--92.25--92.25-
Price to Book Ratio5.12-4.79-5.51-6.66-6.66-
Price-to-Total Gains Ratio-49.78--71.75--42.57--92.25--92.25-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share12.54252
Number of shares79
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.220.16
Usd Total Gains Per Share-0.220.16
Gains per Quarter (79 shares)-17.6712.88
Gains per Year (79 shares)-70.7051.53
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-71-8105242
20-141-152010394
30-212-2230155146
40-283-2940206198
50-353-3650258250
60-424-4360309302
70-495-5070361354
80-566-5780412406
90-636-6490464458
100-707-7200515510

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.016.00.05.9%1.016.00.05.9%1.016.00.05.9%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.014.00.017.6%3.014.00.017.6%3.014.00.017.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.014.00.017.6%3.014.00.017.6%3.014.00.017.6%

Fundamentals of Ryvu

About Ryvu Therapeutics SA

Ryvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.

Fundamental data was last updated by Penke on 2024-04-03 11:19:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Ryvu Therapeutics SA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Ryvu earns for each zł1 of revenue.

  • Above 10% is considered healthy but always compare Ryvu to the Biotechnology industry mean.
  • A Net Profit Margin of -247.9% means that zł-2.48 for each zł1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ryvu Therapeutics SA:

  • The MRQ is -247.9%. The company is making a huge loss. -2
  • The TTM is -200.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-247.9%TTM-200.3%-47.6%
TTM-200.3%YOY-24,511.9%+24,311.6%
TTM-200.3%5Y-4,405.8%+4,205.5%
5Y-4,405.8%10Y-4,405.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-247.9%-200.1%-47.8%
TTM-200.3%-216.8%+16.5%
YOY-24,511.9%-288.3%-24,223.6%
5Y-4,405.8%-449.1%-3,956.7%
10Y-4,405.8%-605.5%-3,800.3%
1.1.2. Return on Assets

Shows how efficient Ryvu is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ryvu to the Biotechnology industry mean.
  • -6.9% Return on Assets means that Ryvu generated zł-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ryvu Therapeutics SA:

  • The MRQ is -6.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.9%TTM-5.4%-1.5%
TTM-5.4%YOY-10.6%+5.2%
TTM-5.4%5Y3.6%-9.0%
5Y3.6%10Y3.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.9%-13.3%+6.4%
TTM-5.4%-12.8%+7.4%
YOY-10.6%-11.7%+1.1%
5Y3.6%-13.9%+17.5%
10Y3.6%-15.7%+19.3%
1.1.3. Return on Equity

Shows how efficient Ryvu is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ryvu to the Biotechnology industry mean.
  • -10.7% Return on Equity means Ryvu generated zł-0.11 for each zł1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ryvu Therapeutics SA:

  • The MRQ is -10.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.7%TTM-8.0%-2.7%
TTM-8.0%YOY-15.1%+7.2%
TTM-8.0%5Y6.3%-14.3%
5Y6.3%10Y6.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.7%-16.9%+6.2%
TTM-8.0%-16.1%+8.1%
YOY-15.1%-15.1%0.0%
5Y6.3%-19.3%+25.6%
10Y6.3%-20.2%+26.5%

1.2. Operating Efficiency of Ryvu Therapeutics SA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ryvu is operating .

  • Measures how much profit Ryvu makes for each zł1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ryvu to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated zł0.00  for each zł1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ryvu Therapeutics SA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-104.3%+104.3%
TTM-104.3%YOY-24,062.1%+23,957.8%
TTM-104.3%5Y-6,953.1%+6,848.8%
5Y-6,953.1%10Y-6,953.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM-104.3%-232.5%+128.2%
YOY-24,062.1%-298.2%-23,763.9%
5Y-6,953.1%-492.1%-6,461.0%
10Y-6,953.1%-632.4%-6,320.7%
1.2.2. Operating Ratio

Measures how efficient Ryvu is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.62 means that the operating costs are zł3.62 for each zł1 in net sales.

Let's take a look of the Operating Ratio trends of Ryvu Therapeutics SA:

  • The MRQ is 3.615. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.504. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.615TTM3.504+0.111
TTM3.504YOY279.571-276.067
TTM3.5045Y81.834-78.330
5Y81.83410Y81.8340.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6153.231+0.384
TTM3.5043.310+0.194
YOY279.5713.890+275.681
5Y81.8345.739+76.095
10Y81.8347.876+73.958

1.3. Liquidity of Ryvu Therapeutics SA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ryvu is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.99 means the company has zł3.99 in assets for each zł1 in short-term debts.

Let's take a look of the Current Ratio trends of Ryvu Therapeutics SA:

  • The MRQ is 3.994. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.451. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.994TTM5.451-1.457
TTM5.451YOY3.828+1.622
TTM5.4515Y4.246+1.204
5Y4.24610Y4.2460.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9943.890+0.104
TTM5.4514.173+1.278
YOY3.8285.344-1.516
5Y4.2466.126-1.880
10Y4.2466.448-2.202
1.3.2. Quick Ratio

Measures if Ryvu is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ryvu to the Biotechnology industry mean.
  • A Quick Ratio of 2.65 means the company can pay off zł2.65 for each zł1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ryvu Therapeutics SA:

  • The MRQ is 2.645. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.053. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.645TTM2.053+0.592
TTM2.053YOY1.722+0.331
TTM2.0535Y2.835-0.782
5Y2.83510Y2.8350.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6453.514-0.869
TTM2.0533.998-1.945
YOY1.7225.380-3.658
5Y2.8356.105-3.270
10Y2.8356.404-3.569

1.4. Solvency of Ryvu Therapeutics SA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ryvu assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ryvu to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.36 means that Ryvu assets are financed with 35.6% credit (debt) and the remaining percentage (100% - 35.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ryvu Therapeutics SA:

  • The MRQ is 0.356. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.315. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.356TTM0.315+0.041
TTM0.315YOY0.293+0.022
TTM0.3155Y0.288+0.027
5Y0.28810Y0.2880.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3560.339+0.017
TTM0.3150.336-0.021
YOY0.2930.271+0.022
5Y0.2880.366-0.078
10Y0.2880.389-0.101
1.4.2. Debt to Equity Ratio

Measures if Ryvu is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ryvu to the Biotechnology industry mean.
  • A Debt to Equity ratio of 55.3% means that company has zł0.55 debt for each zł1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ryvu Therapeutics SA:

  • The MRQ is 0.553. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.464. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.553TTM0.464+0.089
TTM0.464YOY0.418+0.046
TTM0.4645Y0.411+0.054
5Y0.41110Y0.4110.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5530.388+0.165
TTM0.4640.402+0.062
YOY0.4180.335+0.083
5Y0.4110.426-0.015
10Y0.4110.461-0.050

2. Market Valuation of Ryvu Therapeutics SA

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every zł1 in earnings Ryvu generates.

  • Above 15 is considered overpriced but always compare Ryvu to the Biotechnology industry mean.
  • A PE ratio of -11.97 means the investor is paying zł-11.97 for every zł1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ryvu Therapeutics SA:

  • The EOD is -10.580. Based on the earnings, the company is expensive. -2
  • The MRQ is -11.975. Based on the earnings, the company is expensive. -2
  • The TTM is -14.218. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.580MRQ-11.975+1.395
MRQ-11.975TTM-14.218+2.243
TTM-14.218YOY-10.167-4.051
TTM-14.2185Y-22.069+7.851
5Y-22.06910Y-22.0690.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.580-2.264-8.316
MRQ-11.975-2.629-9.346
TTM-14.218-2.680-11.538
YOY-10.167-4.145-6.022
5Y-22.069-6.257-15.812
10Y-22.069-6.254-15.815
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ryvu Therapeutics SA:

  • The EOD is -12.234. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -13.848. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -22.057. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.234MRQ-13.848+1.614
MRQ-13.848TTM-22.057+8.209
TTM-22.057YOY-63.454+41.397
TTM-22.0575Y-40.292+18.235
5Y-40.29210Y-40.2920.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-12.234-2.973-9.261
MRQ-13.848-3.333-10.515
TTM-22.057-3.553-18.504
YOY-63.454-5.605-57.849
5Y-40.292-8.376-31.916
10Y-40.292-8.865-31.427
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ryvu is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.12 means the investor is paying zł5.12 for each zł1 in book value.

Let's take a look of the Price to Book Ratio trends of Ryvu Therapeutics SA:

  • The EOD is 4.524. Based on the equity, the company is fair priced.
  • The MRQ is 5.121. Based on the equity, the company is overpriced. -1
  • The TTM is 4.788. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.524MRQ5.121-0.597
MRQ5.121TTM4.788+0.333
TTM4.788YOY5.514-0.725
TTM4.7885Y6.663-1.874
5Y6.66310Y6.6630.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.5241.896+2.628
MRQ5.1212.115+3.006
TTM4.7882.093+2.695
YOY5.5142.884+2.630
5Y6.6633.542+3.121
10Y6.6633.916+2.747
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Ryvu Therapeutics SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.155-0.906-22%1.881-161%0.660-275%0.660-275%
Book Value Per Share--11.22812.737-12%7.902+42%8.821+27%8.821+27%
Current Ratio--3.9945.451-27%3.828+4%4.246-6%4.246-6%
Debt To Asset Ratio--0.3560.315+13%0.293+21%0.288+24%0.288+24%
Debt To Equity Ratio--0.5530.464+19%0.418+32%0.411+35%0.411+35%
Dividend Per Share----0%-0%-0%-0%
Eps---1.200-1.114-7%-1.122-7%-0.010-99%-0.010-99%
Free Cash Flow Per Share---1.038-1.007-3%0.130-898%-0.731-30%-0.731-30%
Free Cash Flow To Equity Per Share---1.038-1.007-3%0.112-1027%-0.430-59%-0.430-59%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---63.395--------
Intrinsic Value_10Y_min---53.408--------
Intrinsic Value_1Y_max---2.785--------
Intrinsic Value_1Y_min---2.733--------
Intrinsic Value_3Y_max---11.086--------
Intrinsic Value_3Y_min---10.529--------
Intrinsic Value_5Y_max---22.666--------
Intrinsic Value_5Y_min---20.804--------
Market Cap1174501080.000-13%1329408510.0001400502965.100-5%897348881.250+48%1229650002.671+8%1229650002.671+8%
Net Profit Margin---2.479-2.003-19%-245.119+9787%-44.058+1677%-44.058+1677%
Operating Margin----1.0430%-240.6210%-69.5310%-69.5310%
Operating Ratio--3.6153.504+3%279.571-99%81.834-96%81.834-96%
Pb Ratio4.524-13%5.1214.788+7%5.514-7%6.663-23%6.663-23%
Pe Ratio-10.580+12%-11.975-14.218+19%-10.167-15%-22.069+84%-22.069+84%
Price Per Share50.800-13%57.50060.575-5%38.813+48%53.185+8%53.185+8%
Price To Free Cash Flow Ratio-12.234+12%-13.848-22.057+59%-63.454+358%-40.292+191%-40.292+191%
Price To Total Gains Ratio-43.977+12%-49.778-71.748+44%-42.567-14%-92.252+85%-92.252+85%
Quick Ratio--2.6452.053+29%1.722+54%2.835-7%2.835-7%
Return On Assets---0.069-0.054-21%-0.106+54%0.036-290%0.036-290%
Return On Equity---0.107-0.080-26%-0.151+42%0.063-270%0.063-270%
Total Gains Per Share---1.155-0.906-22%1.881-161%0.660-275%0.660-275%
Usd Book Value--64093264.80072709334.100-12%45106529.375+42%50351155.865+27%50351155.865+27%
Usd Book Value Change Per Share---0.285-0.224-22%0.464-161%0.163-275%0.163-275%
Usd Book Value Per Share--2.7723.145-12%1.951+42%2.178+27%2.178+27%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.296-0.275-7%-0.277-7%-0.002-99%-0.002-99%
Usd Free Cash Flow---5925600.000-5748387.525-3%742675.200-898%-4175651.445-30%-4175651.445-30%
Usd Free Cash Flow Per Share---0.256-0.249-3%0.032-898%-0.181-30%-0.181-30%
Usd Free Cash Flow To Equity Per Share---0.256-0.249-3%0.028-1027%-0.106-59%-0.106-59%
Usd Market Cap289984316.652-13%328230961.119345784182.083-5%221555438.781+48%303600585.659+8%303600585.659+8%
Usd Price Per Share12.543-13%14.19714.956-5%9.583+48%13.131+8%13.131+8%
Usd Profit---6852462.600-5685613.200-17%-5171443.950-25%392629.762-1845%392629.762-1845%
Usd Revenue--2764045.5002892433.500-4%2409471.854+15%1646709.629+68%1646709.629+68%
Usd Total Gains Per Share---0.285-0.224-22%0.464-161%0.163-275%0.163-275%
 EOD+3 -5MRQTTM+3 -29YOY+15 -175Y+11 -2110Y+11 -21

3.2. Fundamental Score

Let's check the fundamental score of Ryvu Therapeutics SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-10.580
Price to Book Ratio (EOD)Between0-14.524
Net Profit Margin (MRQ)Greater than0-2.479
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.645
Current Ratio (MRQ)Greater than13.994
Debt to Asset Ratio (MRQ)Less than10.356
Debt to Equity Ratio (MRQ)Less than10.553
Return on Equity (MRQ)Greater than0.15-0.107
Return on Assets (MRQ)Greater than0.05-0.069
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Ryvu Therapeutics SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5023.555
Ma 20Greater thanMa 5054.395
Ma 50Greater thanMa 10056.986
Ma 100Greater thanMa 20057.524
OpenGreater thanClose50.900
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Retained Earnings  92,103-17,59874,505-28,50745,998-18,25427,744-27,754-10



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in PLN. All numbers in thousands.

Summary
Total Assets403,202
Total Liabilities143,610
Total Stockholder Equity259,592
 As reported
Total Liabilities 143,610
Total Stockholder Equity+ 259,592
Total Assets = 403,202

Assets

Total Assets403,202
Total Current Assets278,393
Long-term Assets124,809
Total Current Assets
Cash And Cash Equivalents 57,939
Short-term Investments 175,205
Net Receivables 9,187
Inventory 2,118
Other Current Assets 9,766
Total Current Assets  (as reported)278,393
Total Current Assets  (calculated)254,215
+/- 24,178
Long-term Assets
Property Plant Equipment 77,554
Intangible Assets 6,337
Long-term Assets Other 6,534
Long-term Assets  (as reported)124,809
Long-term Assets  (calculated)90,425
+/- 34,384

Liabilities & Shareholders' Equity

Total Current Liabilities69,703
Long-term Liabilities73,907
Total Stockholder Equity259,592
Total Current Liabilities
Short Long Term Debt 127
Accounts payable 23,142
Other Current Liabilities 2,207
Total Current Liabilities  (as reported)69,703
Total Current Liabilities  (calculated)25,476
+/- 44,227
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt779
Long-term Liabilities  (as reported)73,907
Long-term Liabilities  (calculated)779
+/- 73,128
Total Stockholder Equity
Total Stockholder Equity (as reported)259,592
Total Stockholder Equity (calculated)0
+/- 259,592
Other
Capital Stock9,248
Common Stock Shares Outstanding 23,120
Net Invested Capital 259,719
Net Working Capital 208,690
Property Plant and Equipment Gross 139,898



Balance Sheet

Currency in PLN. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
> Total Assets 
183,630
178,263
167,837
294,832
295,640
282,151
253,343
233,896
228,813
201,402
179,372
169,838
474,977
449,183
425,254
439,824
403,202
403,202439,824425,254449,183474,977169,838179,372201,402228,813233,896253,343282,151295,640294,832167,837178,263183,630
   > Total Current Assets 
89,976
75,811
53,682
173,884
172,362
157,018
126,758
106,566
104,248
79,114
64,054
57,176
367,930
334,381
238,669
318,679
278,393
278,393318,679238,669334,381367,93057,17664,05479,114104,248106,566126,758157,018172,362173,88453,68275,81189,976
       Cash And Cash Equivalents 
46,170
36,370
0
0
43,150
122,204
84,154
81,019
83,236
64,804
44,626
43,680
101,917
300,839
93,765
79,657
57,939
57,93979,65793,765300,839101,91743,68044,62664,80483,23681,01984,154122,20443,1500036,37046,170
       Short-term Investments 
0
0
0
0
24,969
24,965
29,967
9,990
4,994
0
0
0
0
2,157
107,992
178,265
175,205
175,205178,265107,9922,15700004,9949,99029,96724,96524,9690000
       Net Receivables 
1,648
10,138
1,523
2,014
7,948
6,751
6,863
9,518
11,741
9,574
14,061
7,823
259,893
10,777
28,038
20,841
9,187
9,18720,84128,03810,777259,8937,82314,0619,57411,7419,5186,8636,7517,9482,0141,52310,1381,648
       Inventory 
1,586
1,586
904
904
1,676
1,676
3,180
3,180
1,957
1,957
1,763
1,763
1,759
1,759
2,036
2,036
2,118
2,1182,0362,0361,7591,7591,7631,7631,9571,9573,1803,1801,6761,6769049041,5861,586
       Other Current Assets 
1,242
885
611
381
976
668
703
919
577
724
961
1,388
1,484
982
3,995
1,459
9,766
9,7661,4593,9959821,4841,3889617245779197036689763816118851,242
   > Long-term Assets 
0
0
0
0
123,278
125,132
126,586
127,329
124,565
122,288
115,318
112,661
107,047
114,803
186,586
121,145
124,809
124,809121,145186,586114,803107,047112,661115,318122,288124,565127,329126,586125,132123,2780000
       Property Plant Equipment 
66,189
73,493
82,023
88,458
91,162
91,144
93,786
92,845
91,182
88,925
88,178
84,959
82,219
80,093
78,356
77,870
77,554
77,55477,87078,35680,09382,21984,95988,17888,92591,18292,84593,78691,14491,16288,45882,02373,49366,189
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000
       Intangible Assets 
2,924
3,634
3,622
3,673
2,319
2,400
2,403
2,860
3,044
3,139
3,248
4,090
4,276
4,285
0
0
6,337
6,337004,2854,2764,0903,2483,1393,0442,8602,4032,4002,3193,6733,6223,6342,924
       Accumulated depreciation 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
1
1
1
1
1
1
1
0
0
6,534
6,5340011111110000000
> Total Liabilities 
63,050
61,990
55,866
60,155
71,920
71,993
60,327
55,568
59,392
50,368
57,136
55,733
131,585
120,399
121,973
153,525
143,610
143,610153,525121,973120,399131,58555,73357,13650,36859,39255,56860,32771,99371,92060,15555,86661,99063,050
   > Total Current Liabilities 
30,616
27,780
24,009
31,007
33,813
35,054
27,507
23,694
36,200
24,393
31,570
31,237
44,814
36,734
58,440
68,949
69,703
69,70368,94958,44036,73444,81431,23731,57024,39336,20023,69427,50735,05433,81331,00724,00927,78030,616
       Short Long Term Debt 
0
0
0
0
814
814
817
841
833
876
891
903
874
629
466
309
127
1273094666298749038918768338418178148140000
       Accounts payable 
0
0
0
0
6,261
12,225
11,175
7,271
11,689
8,909
12,954
13,532
12,579
10,922
17,684
28,982
23,142
23,14228,98217,68410,92212,57913,53212,9548,90911,6897,27111,17512,2256,2610000
       Other Current Liabilities 
0
0
0
0
19,160
16,279
8,519
7,127
16,902
8,361
9,675
7,555
18,637
17,718
31,531
1
2,207
2,207131,53117,71818,6377,5559,6758,36116,9027,1278,51916,27919,1600000
   > Long-term Liabilities 
0
0
0
0
38,106
36,939
32,820
31,874
23,192
25,975
25,567
24,496
86,771
83,665
63,533
84,576
73,907
73,90784,57663,53383,66586,77124,49625,56725,97523,19231,87432,82036,93938,1060000
       Long term Debt Total 
5,918
8,879
5,851
4,942
4,327
0
0
0
0
0
0
0
0
0
0
0
0
0000000000004,3274,9425,8518,8795,918
       Other Liabilities 
0
0
0
0
33,780
33,155
29,369
28,893
20,873
24,015
23,909
23,219
0
0
53,818
0
0
0053,8180023,21923,90924,01520,87328,89329,36933,15533,7800000
> Total Stockholder Equity
120,580
116,273
111,971
234,677
223,721
210,157
193,017
178,328
169,422
151,034
122,235
114,104
343,392
328,784
303,281
286,299
259,592
259,592286,299303,281328,784343,392114,104122,235151,034169,422178,328193,017210,157223,721234,677111,971116,273120,580
   Common Stock
6,388
6,388
6,388
7,342
7,342
7,342
7,342
7,342
7,342
7,342
7,342
7,342
0
0
9,248
0
0
009,248007,3427,3427,3427,3427,3427,3427,3427,3427,3426,3886,3886,388
   Retained Earnings 
289,981
285,673
281,372
269,235
261,539
247,976
223,732
200,914
184,005
157,469
120,549
108,748
92,103
74,505
45,998
27,744
-10
-1027,74445,99874,50592,103108,748120,549157,469184,005200,914223,732247,976261,539269,235281,372285,673289,981
   Capital Surplus 
145,189
145,189
145,189
279,077
279,063
279,063
279,063
279,063
0
0
0
0
0
0
0
0
0
000000000279,063279,063279,063279,063279,077145,189145,189145,189
   Treasury Stock00000000000000000
   Other Stockholders Equity 00-271,71300-281,049-284,719-292,840-300,988-308,991-317,120-324,224-324,224-320,977-320,977-320,977-320,977



Balance Sheet

Currency in PLN. All numbers in thousands.




Cash Flow

Currency in PLN. All numbers in thousands.




Income Statement

Currency in PLN. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue46,860
Cost of Revenue-17,554
Gross Profit29,30629,306
 
Operating Income (+$)
Gross Profit29,306
Operating Expense-144,235
Operating Income-97,375-114,929
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense144,2350
 
Net Interest Income (+$)
Interest Income13,833
Interest Expense-97
Other Finance Cost-0
Net Interest Income13,736
 
Pretax Income (+$)
Operating Income-97,375
Net Interest Income13,736
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-92,112-97,375
EBIT - interestExpense = -97
-92,112
-92,015
Interest Expense97
Earnings Before Interest and Taxes (EBIT)0-92,015
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-92,112
Tax Provision-0
Net Income From Continuing Ops-92,112-92,112
Net Income-92,112
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-13,736
 

Technical Analysis of Ryvu
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ryvu. The general trend of Ryvu is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ryvu's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ryvu Therapeutics SA.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 51.70 < 53.50 < 54.30.

The bearish price targets are: 49.20 > 45.00 > 43.50.

Tweet this
Ryvu Therapeutics SA Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ryvu Therapeutics SA. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ryvu Therapeutics SA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ryvu Therapeutics SA. The current macd is -1.4297151.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ryvu price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Ryvu. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Ryvu price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Ryvu Therapeutics SA Daily Moving Average Convergence/Divergence (MACD) ChartRyvu Therapeutics SA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ryvu Therapeutics SA. The current adx is 34.82.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Ryvu shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Ryvu Therapeutics SA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ryvu Therapeutics SA. The current sar is 55.16.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Ryvu Therapeutics SA Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ryvu Therapeutics SA. The current rsi is 23.56. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Ryvu Therapeutics SA Daily Relative Strength Index (RSI) ChartRyvu Therapeutics SA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ryvu Therapeutics SA. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ryvu price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Ryvu Therapeutics SA Daily Stochastic Oscillator ChartRyvu Therapeutics SA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ryvu Therapeutics SA. The current cci is -222.79218078.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Ryvu Therapeutics SA Daily Commodity Channel Index (CCI) ChartRyvu Therapeutics SA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ryvu Therapeutics SA. The current cmo is -66.75910029.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Ryvu Therapeutics SA Daily Chande Momentum Oscillator (CMO) ChartRyvu Therapeutics SA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ryvu Therapeutics SA. The current willr is -82.01438849.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Ryvu Therapeutics SA Daily Williams %R ChartRyvu Therapeutics SA Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ryvu Therapeutics SA.

Ryvu Therapeutics SA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ryvu Therapeutics SA. The current atr is 1.32605733.

Ryvu Therapeutics SA Daily Average True Range (ATR) ChartRyvu Therapeutics SA Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ryvu Therapeutics SA. The current obv is 594,562.

Ryvu Therapeutics SA Daily On-Balance Volume (OBV) ChartRyvu Therapeutics SA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ryvu Therapeutics SA. The current mfi is 38.10.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Ryvu Therapeutics SA Daily Money Flow Index (MFI) ChartRyvu Therapeutics SA Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ryvu Therapeutics SA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Ryvu Therapeutics SA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ryvu Therapeutics SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5023.555
Ma 20Greater thanMa 5054.395
Ma 50Greater thanMa 10056.986
Ma 100Greater thanMa 20057.524
OpenGreater thanClose50.900
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Ryvu with someone you think should read this too:
  • Are you bullish or bearish on Ryvu? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ryvu? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ryvu Therapeutics SA

I send you an email if I find something interesting about Ryvu Therapeutics SA.


Comments

How you think about this?

Leave a comment

Stay informed about Ryvu Therapeutics SA.

Receive notifications about Ryvu Therapeutics SA in your mailbox!